Akron Biotechnology, LLC And Cognate BioServices, Inc. Announce Strategic Partnership

BOCA RATON, Fla.--(BUSINESS WIRE)--Cognate BioServices, Inc. and Akron Biotechnology, LLC are pleased to announce a strategic partnership that brings two industry leaders together to provide a more complete package of services to their clients. Cognate is a leader in the provision of cGMP manufacturing services and regulatory support to companies and institutions engaged in the development of regenerative medicine and cell-based products and therapies. Akron Biotech is an innovative supplier of validated reagents, solutions and technologies to the cell therapy industry. Their relationship strengthens both companies and will unify their resources to better serve growing market demands internationally.

“This partnership is a unique opportunity to integrate the offerings of our two companies to meet the growing needs of the industry by strategically reducing the cost of goods through enabling solutions and procurement of raw materials in a cost-efficient manner for our customers and Cognate clients.”

Akron Biotech founder and CEO Claudia Zylberberg, PhD, stated, “This partnership is a unique opportunity to integrate the offerings of our two companies to meet the growing needs of the industry by strategically reducing the cost of goods through enabling solutions and procurement of raw materials in a cost-efficient manner for our customers and Cognate clients.”

J. Kelly Ganjei, CEO of Cognate BioServices, added, “We believe that offering a more full service integration with specific key supply chain demands provides us and our clients a competitive advantage in this field. Dr. Zylberberg and her team have built a brand around quality and innovation, two attributes that Cognate requires of itself internally. We are very excited about continuing to expand our collective offerings to our clients in the US and internationally.”

The companies will continue to operate as separate entities, with each company focusing on further developing its core competencies while contemporaneously leveraging each other’s strengths to advance new cell therapy-based treatments from workbench to the clinic. For Cognate’s core, these competencies include cGMP manufacturing, scale up, validation and process development through specialized infrastructure and expertise to support clients through all aspects of cell-based drug development up to and including commercialization. Akron’s core competencies include the production and distribution of validated raw materials and solutions to cell therapy clients, as well as innovating new products and technologies for the regenerative medicine space.

About Akron Biotech

As an ISO certified global supplier, Akron Biotech manufactures ancillary materials and provides novel technologies for cell therapy and regenerative medicine discovery, development, and commercialization, meeting the industry’s quality standards worldwide. Akron Biotech has a strategic focus on delivering biological materials, technologies, and services for the regenerative medicine industry. For more information please visit www.akronbiotech.com.

About Cognate BioServices

Cognate BioServices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today. For more information please visit www.cognatebioservices.com.